AzurRx BioPharma, Inc.

(NetworkNewsWire) With more than a century of combined experience spanning the gamut from pancreas/GI tract issues in hepato-gastroenterology and infectious disease to the development of novel non-systemic (localized) therapeutic biologics and proteomics (protein engineering), the AzurRx BioPharma, Inc. (NASDAQ:AZRX) core science team is the real strength behind the company's developing portfolio of recombinant therapies.

(NetworkNewsWire) Exocrine Pancreatic Insufficiency, or EPI, is a problem in a person's digestive system. Simply put, EPI is when the pancreas cannot produce enough of the enzymes that the body requires to break down and absorb nutrients. Unfortunately, this means that the body is unable to absorb the right fats and nutrients, often leading to weight loss.<br /><br />There are a number of causes for EPI, such as inflammation of the pancreas; effects from surgery on the pancreas, intestines, or stomach; or even an inherited disease such as cystic fibrosis, Shwachman-Diamond syndrome, Crohn's Disease, diabetes, or celiac disease. Symptoms do vary, but normally the patient will feel a pain or tenderness in the abdomen, problems with bowel movements, flatulence, and a feeling of being full.<br /><br />Today, there has been a rise in the number of people with EPI, and this has been largely attributed to an increase in the number of patients diagnosed with diabetes and cystic fibrosis (CF). ...